191 related articles for article (PubMed ID: 29124243)
1. Establishment of Korean prostate cancer database by the Korean Urological Oncology Society.
Ahn H; Kim HJ; Jeon SS; Kwak C; Sung GT; Kwon TG; Park JY; Paick SH
Investig Clin Urol; 2017 Nov; 58(6):434-439. PubMed ID: 29124243
[TBL] [Abstract][Full Text] [Related]
2. Active Surveillance for Men with Intermediate Risk Prostate Cancer.
Agrawal V; Ma X; Hu JC; Barbieri CE; Nagar H
J Urol; 2021 Jan; 205(1):115-121. PubMed ID: 32658588
[TBL] [Abstract][Full Text] [Related]
3. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
[TBL] [Abstract][Full Text] [Related]
4. Factors Influencing Selection of Active Surveillance for Localized Prostate Cancer.
Liu J; Womble PR; Merdan S; Miller DC; Montie JE; Denton BT;
Urology; 2015 Nov; 86(5):901-5. PubMed ID: 26358397
[TBL] [Abstract][Full Text] [Related]
5. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
6. Gleason inflation 1998-2011: a registry study of 97,168 men.
Danneman D; Drevin L; Robinson D; Stattin P; Egevad L
BJU Int; 2015 Feb; 115(2):248-55. PubMed ID: 24552193
[TBL] [Abstract][Full Text] [Related]
7. Patterns of treatment of patients with prostate cancer initially managed with surveillance: results from The CaPSURE database. Cancer of the Prostate Strategic Urological Research Endeavor.
Koppie TM; Grossfeld GD; Miller D; Yu J; Stier D; Broering JM; Lubeck D; Henning JM; Flanders SC; Carroll PR
J Urol; 2000 Jul; 164(1):81-8. PubMed ID: 10840429
[TBL] [Abstract][Full Text] [Related]
8. Trends of the primary therapy for patients with prostate cancer in Nara uro-oncological research group (NUORG): a comparison between the CaPSURE data and the NUORG data.
Tanaka N; Fujimoto K; Hirayama A; Yoneda T; Yoshida K; Hirao Y
Jpn J Clin Oncol; 2010 Jun; 40(6):588-92. PubMed ID: 20299498
[TBL] [Abstract][Full Text] [Related]
9. Treatment patterns for older veterans with localized prostate cancer.
Hoffman RM; Shi Y; Freedland SJ; Keating NL; Walter LC
Cancer Epidemiol; 2015 Oct; 39(5):769-77. PubMed ID: 26228494
[TBL] [Abstract][Full Text] [Related]
10. UK radical prostatectomy outcomes and surgeon case volume: based on an analysis of the British Association of Urological Surgeons Complex Operations Database.
Vesey SG; McCabe JE; Hounsome L; Fowler S
BJU Int; 2012 Feb; 109(3):346-54. PubMed ID: 21771246
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
[TBL] [Abstract][Full Text] [Related]
12. Redefining high-risk prostate cancer based on distant metastases and mortality after high-dose radiotherapy with androgen deprivation therapy.
Tendulkar RD; Reddy CA; Stephans KL; Ciezki JP; Klein EA; Mahadevan A; Kupelian PA
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1397-404. PubMed ID: 21665379
[TBL] [Abstract][Full Text] [Related]
13. Active treatment in low-risk prostate cancer: a population-based study.
Roy S; Hyndman ME; Danielson B; Fairey A; Lee-Ying R; Cheung WY; Afzal AR; Xu Y; Abedin T; Quon HC
Curr Oncol; 2019 Aug; 26(4):e535-e540. PubMed ID: 31548822
[TBL] [Abstract][Full Text] [Related]
14. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
15. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above.
Kupelian PA; Buchsbaum JC; Elshaikh M; Reddy CA; Zippe C; Klein EA
Cancer; 2002 Dec; 95(11):2302-7. PubMed ID: 12436435
[TBL] [Abstract][Full Text] [Related]
16. Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy.
Zietman AL; Thakral H; Wilson L; Schellhammer P
J Urol; 2001 Nov; 166(5):1702-6. PubMed ID: 11586206
[TBL] [Abstract][Full Text] [Related]
17. Clinico-pathologic characterisation of metastatic prostate cancer in the Radiotherapy and Oncology Department, Ahmadu Bello University Teaching Hospital, Zaria-Nigeria: 2006-2009.
Adewuyi SA; Mbibu NH; Samaila MO; Ketiku KK; Durosinmi-Etti FA
Niger Postgrad Med J; 2013 Mar; 20(1):45-51. PubMed ID: 23661210
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer in younger and older patients: do we treat them differently?
Situmorang GR; Umbas R; Mochtar CA; Santoso RB
Asian Pac J Cancer Prev; 2012; 13(9):4577-80. PubMed ID: 23167383
[TBL] [Abstract][Full Text] [Related]
19. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.
Vellekoop A; Loeb S; Folkvaljon Y; Stattin P
J Urol; 2014 Feb; 191(2):350-7. PubMed ID: 24071481
[TBL] [Abstract][Full Text] [Related]
20. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]